Search

Your search keyword '"Meazza C"' showing total 398 results
Start Over Author "Meazza C"
398 results on '"Meazza C"'

1. TREATING LYMPHOMA IN THE PANDEMIC ERA: WHAT WE LEARNED FROM OUR EXPERIENCE AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Author

Gattuso, G., primary, Biassoni, V., additional, Podda, M., additional, Meazza, C., additional, Chiaravalli, S., additional, Nigro, O., additional, Sironi, G., additional, Livellara, V., additional, Puma, N., additional, Bergamaschi, L., additional, Terenziani, M., additional, Spreafico, F., additional, Massimino, M., additional, and Schiavello, E., additional

Published
2022
Full Text
View/download PDF

2. ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)

Author

Palmerini, E, Meazza, C, Tamburini, A, Bisogno, G, Ferraresi, V, Asaftei, S, Milano, GM, Coccoli, L, Manzitti, C, Luksch, R, Donati, DM, Serra, M, Bertulli, R, Gambarotti, M, Favre, C, Longhi, A, Casali, PG, Picci, P, Fagioli, F, Ferrari, S, Palmerini, E, Meazza, C, Tamburini, A, Bisogno, G, Ferraresi, V, Asaftei, S, Milano, GM, Coccoli, L, Manzitti, C, Luksch, R, Donati, DM, Serra, M, Bertulli, R, Gambarotti, M, Favre, C, Longhi, A, Casali, PG, Picci, P, Fagioli, F, and Ferrari, S

Subjects
high grade osteosarcoma
Published
2020

3. 1962P phase II study for nonmetastatic extremity high-grade osteosarcoma in pediatric and AYA patients with a risk-adapted strategy based on P-glycoprotein expression by the ISG (ISG/OS-2): A correlative study on tumor microenvironment

Author

Palmerini, E., Sapienza, M.R., S. Pileri, Righi, A., Agostinelli, C., Franchi, A., Parafioriti, A., Meazza, C., Ferraresi, V., Asafteri, S.D., Coccoli, L., Tamburini, A., Gambarotti, M., Serra, M., Cesari, M., Donati, D.M., Fagioli, F., Scotlandi, K., Ibrahim, T., and Ferrari, S.

Published
2023
Full Text
View/download PDF

10. 443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

Author

Gaspar, N., primary, Campbell-Hewson, Q., additional, Bielack, S.S., additional, Campbell, M., additional, Bautista, F., additional, Meazza, C., additional, Janeway, K., additional, Dela Cruz, F.S., additional, Whittle, S., additional, Morgenstern, D.A., additional, Dutta, L., additional, McKenzie, J., additional, O'Hara, K., additional, Huang, J., additional, Okpara, C.E., additional, Bidadi, B., additional, Koh, K-N., additional, and Moreland, B., additional

Published
2020
Full Text
View/download PDF

11. 1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

Author

Gaspar, N., primary, Campbell-Hewson, Q., additional, Bielack, S.S., additional, Campbell, M., additional, Bautista, F., additional, Meazza, C., additional, Janeway, K., additional, Dela Cruz, F.S., additional, Whittle, S.B., additional, Morgenstern, D.A., additional, Dutta, L., additional, McKenzie, J., additional, O'Hara, K., additional, Huang, J., additional, Okpara, C.E., additional, Bidadi, B., additional, Koh, K-N., additional, and Morland, B., additional

Published
2020
Full Text
View/download PDF

12. 1625MO ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)

Author

Palmerini, E., primary, Meazza, C., additional, Tamburini, A., additional, Bisogno, G., additional, Ferraresi, V., additional, Asaftei, S., additional, Milano, G.M., additional, Coccoli, L., additional, Manzitti, C., additional, Luksch, R., additional, Donati, D.M., additional, Serra, M., additional, Bertulli, R., additional, Gambarotti, M., additional, Favre, C., additional, Longhi, A., additional, Casali, P.G., additional, Picci, P., additional, Fagioli, F., additional, and Ferrari, S., additional

Published
2020
Full Text
View/download PDF

20. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)

Author

Ferrari, S, Meazza, C, Palmerini, E, Tamburini, A, Fagioli, F, Cozza, R, Ferraresi, V, Bisogno, G, Mascarin, M, Cefalo, G, Manfrini, M, Capanna, R, Biagini, R, DONATI, DAVIDE MARIA, PICCI, PIERO, Ferrari, S, Meazza, C, Palmerini, E, Tamburini, A, Fagioli, F, Cozza, R, Ferraresi, V, Bisogno, G, Mascarin, M, Cefalo, G, Manfrini, M, Capanna, R, Biagini, R, Donati, D, and Picci, P

Subjects
Adult, Male, 0301 basic medicine, Cancer Research, Adolescent, nonmetastatic osteosarcoma, neoadjuvant chemotherapy, Bone Neoplasms, Methotrexate, Neoadjuvant chemotherapy, Osteosarcoma, Tumor necrosis, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Child, Cisplatin, Disease-Free Survival, Doxorubicin, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Ifosfamide, Italy, Neoadjuvant Therapy, Prospective Studies, Randomized Controlled Trials as Topic, Survival Analysis, Treatment Outcome, Young Adult, Medicine (all), tumor necrosis, methotrexate, 03 medical and health sciences, 0302 clinical medicine, osteosarcoma, Chemotherapy, Adjuvant, General Medicine, neoadjuvant chemotherapy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis
Abstract

BACKGROUND: Based on the results of the ISG/OS-1 study, the MAP regimen (methotrexate [MTX], doxorubicin [ADM] and cisplatin [CDP] with the addition of ifosfamide [IFO] in poor-responder patients) was investigated in patients with nonmetastatic osteosarcoma of the extremity (ISG/OS-Oss study). PATIENTS AND METHODS: Compared with the ISG/OS-1 study (cumulative doses: ADM 420 mg/m(2), MTX 120 g/m(2), CDP 600 mg/m(2), IFO 30 g/m(2)), the ISG/OS-Oss study reduced the number of MTX cycles from 10 to 5 (cumulative MTX dose: 60 g/m(2)) in order to diminish treatment duration and toxicity. RESULTS: From January 2007 to June 2011, 171 patients (median age 16 years, 60% males) were registered. The limb salvage rate was 94% and the good pathologic response rate 51% (these figures were 92% and 48%, respectively, in the ISG/OS-1 study). At a median follow-up of 39 months (range, 4-80), the 5-year overall survival rate was 80% (95% CI, 73%-87%) and the event-free survival was 50% (95% CI, 39%-59%). For comparison, the 5-year overall and event-free survival rates in ISG/OS-1 were 73% (95% CI, 65%-81%) and 64% (95% CI, 56%-73%), respectively. CONCLUSIONS: This study confirms that in nonmetastatic osteosarcoma of the extremity, conservative surgery in more than 90% and a good pathologic response rate of 50% can be expected with primary chemotherapy based on the MAP regimen. The response and resection rates in the ISG/OS-Oss study are in the same range as those of the previous study, whereas the event-free survival is lower than that previously achieved. Since the only difference between the two studies was the cumulative dose of postoperatively given MTX, our data support the importance of the cumulative dose of MTX in the MAP regimen.

Published
2014

21. Single-day trimethoprim/sulfamethoxazole prophylaxis for pneumocystis pneumonia in children with cancer

Author

Caselli, D, Petris, Mg, Rondelli, R, Carraro, F, Colombini, A, Muggeo, P, Ziino, Melchionda, F, Russo, G, Pierani, P, Soncini, E, Desantis, R, Zanazzo, G, Barone, A, Cesaro, Simone, Cellini, M, Mura, R, Milano, Gm, Meazza, C, Cicalese, Mp, Tropia, S, De Masi, S, Castagnola, E, Aricò, M, Infectious Diseases Working Group of the Associazione Italiana Ematologia Oncologia Pediatrica, Caselli, D, Petris, Mg, Rondelli, R, Carraro, F, Colombini, A, Muggeo, P, Ziino, O, Melchionda, F, Russo, G, Pierani, P, Soncini, E, Desantis, R, Zanazzo, G, Barone, A, Cesaro, S, Cellini, M, Mura, R, Milano, Gm, Meazza, C, Cicalese, Mp, Tropia, S, De Masi, S, Castagnola, E, Aricò, M, and Infectious Diseases Working Group of the Associazione Italiana Ematologia Oncologia, Pediatrica.

Subjects
medicine.medical_specialty, Pneumocystis carinii, Pneumocystis pneumonia, Drug Administration Schedule, Anti-Infective Agents, Internal medicine, Trimethoprim, Sulfamethoxazole Drug Combination, medicine, Humans, Cumulative incidence, Prospective Studies, Child, Prospective cohort study, Intention-to-treat analysis, Dose-Response Relationship, Drug, business.industry, Pneumocystis (jirovecii [carinii]) pneumonia (PCP), Incidence, Pneumonia, Pneumocystis, Sulfamethoxazole, trimethoprim/sulfamethoxazole, prophylaxis against PCP, medicine.disease, Trimethoprim, Surgery, Pneumonia, Regimen, Treatment Outcome, Italy, Hematologic Neoplasms, Pediatrics, Perinatology and Child Health, business, Follow-Up Studies, medicine.drug
Abstract

Objective To determine whether a simplified, 1-day/week regimen of trimethoprim/sulfamethoxazole is sufficient to prevent Pneumocystis (jirovecii [carinii]) pneumonia (PCP). Current recommended regimens for prophylaxis against PCP range from daily administration to 3 consecutive days per week dosing. Study design A prospective survey of the regimens adopted for the PCP prophylaxis in all patients treated for childhood cancer at pediatric hematology-oncology centers of the Associazione Italiana Ematologia Oncologia Pediatrica. Results The 20 centers participating in the study reported a total of 2466 patients, including 1093 with solid tumor and 1373 with leukemia/lymphoma (or primary immunodeficiency; n = 2). Of these patients, 1371 (55.6%) received the 3-day/week prophylaxis regimen, 406 (16.5%) received the 2-day/week regimen, and 689 (27.9%), including 439 with leukemia/lymphoma, received the 1-day/week regimen. Overall, only 2 cases of PCP (0.08%) were reported, both in the 2-day/week group. By intention to treat, the cumulative incidence of PCP at 3 years was 0.09% overall (95% CI, 0.00-0.40%) and 0.51% for the 2-day/week group (95% CI, 0.10%-2.00%). Remarkably, both patients who failed had withdrawn from prophylaxis. Conclusion A single-day course of prophylaxis with trimethoprim/sulfamethoxazole may be sufficient to prevent PCP in children with cancer undergoing intensive chemotherapy regimens. This simplified strategy might have implications for the emerging need for PCP prophylaxis in other patients subjected to the increased use of biological and nonbiological agents that induce higher levels of immune suppression, such as those with rheumatic diseases.

Published
2014

23. L’università dell’Utopia. La Statale di Milano negli anni Settanta

Author

Coen Porosini, A., Dionigi, R., Generali, D., Botta, M., Capanna, M., Bellini, R., Baldini, F., Carrozzini, G., Veneziano, R., Martignoni, G. M., Giannitrapani, P., Vedibene, M., Brebbia, G., Meazza, C., Petitot, J., Sini, C., Bianca, M., Broggini, G., Cambria, F., Rodríguez, R. A., Fabbrichesi, R., Handjaras, L., Maiorca, B., Biuso, A. G., Agazzi, E., Heinzmann, G., Coliva, A., Gonzalez, W. J., Arrojo, M. J., Coniglione, F., Negro, M., Chiffi, D., Sabatini, N., Schiavio, F., Taramelli, R., Lenk, H., Maring, M., Cambi, F., Buzzoni, M., Galuzzi, M., Quaranta, M., Renzi, E., Ferri, M. B., Paladini, A., Giannì, I., Scaramuzza, G., Dino, O., DALLA VIGNA, PIERRE ALESSANDRO, Paganini, G., Galli, S. B., Pozzi, P., Kemp, P., Lazzari, M., Marinotti, A., Colonnello, P., Piccari, P., Quarta, A., Vinti, C., Micheli, G., Bazhanov, V. A., Panza, M., Cimino, G., Luzzini, F., Vaccari, E., Wolenski, J., Rossi, A., Bertagna, G., Bartolini, R., Tussi, T., Scolozzi, E., Hagström, E., Ponzellini, V., Patti, A., Barile, S., Veca, S., Frascanetti Brondino, Y., Visconti, K., Orecchia, A. M., Sandrini, M. G., Dobner, C., Moccia, N., Brondino, M., Velázquez, L., Brondino, L., Papi, F., Brissa, E., de Paoli, M., Riccobono, M. G., Santi, G., Pasetti, C., and Martignoni, G.

Published
2015

24. COLONIZZAZIONE ED INFEZIONE DA ENTEROBACTERIACEAE RESISTENTI AI CARBAPENEMICI NEI BAMBINI ITALIANI INTRATTAMENTO CON CHEMIOTERAPIA

Author

Caselli, D., Cesaro, Simone, Fagioli, F., Carraro, F., Ziino, O., Zanazzo, G., Meazza, C., Colombini, A., Muggeo, P. E., Mura, R., Orofino, M. G., Giacchino, M., La Spina, M., Consarino, C., Tucci, F., Barone, A., Cellini, M., Perruccio, K., Bandettini, R., Rondelli, R., De Masi, S., Aricò, M., and Castagnola, E. .

Subjects
antibiotico-resistenza, infezioni batteriche, sepsi, infezioni batteriche, antibiotico-resistenza, sepsi
Published
2015

25. Infectious Diseases Working Group of the Associazione Italiana Ematologia Oncologia Pediatrica. Single-Day Cotrimoxazole Prophylaxis For Pneumocystis Jiroveci (Carinii) Pneumonia In Children With Cancer

Author

Caselli, D, Petris, Mg, Rondelli, R, Carraro, F, Colombini, A, Muggeo, P, Ziino, O, Melchionda, F, Russo, Giovanna, Pierani, P, Soncini, E, Desantis, R, Zanazzo, G, Barone, A, Cesaro, S, Cellini, M, Mura, R, Milano, Gm, Meazza, C, Cicalese, Mp, Tropia, S, De Masi, S, Castagnola, E, and Aricò, M.

Subjects
Pneumocystis (jirovecii [carinii]) pneumonia, Associazione Italiana Ematologia Oncologia Pediatrica, Sulfamethoxazole Trimethoprim
Published
2014

26. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone

Author

Palmerini, E., primary, Jones, R. L., additional, Marchesi, E., additional, Paioli, A., additional, Cesari, M., additional, Longhi, A., additional, Meazza, C., additional, Coccoli, L., additional, Fagioli, F., additional, Asaftei, S., additional, Grignani, G., additional, Tamburini, A., additional, Pollack, S. M., additional, Picci, P., additional, and Ferrari, S., additional

Published
2016
Full Text
View/download PDF

29. Profilassi della polmonite da pneumocystisjiroveci (carinii) in bambini in in chemioterapia: è sufficiente il cotrimoxazolo un giorno alla settimana

Author

Caselli, D., Petris, M. G., Carraro, F., Colombini, A., Muggeo, P., Soncini, E., Zimo, O., Meazza, C., Melchionda, F., de Santis, R., Barone, A., Cellini, M., Milano, G. M., Zanazzo, G., Cesaro, Simone, Mura, R., Cicalese, M. P., De Masi, S., Castagnola, E., and Aricò, M.

Subjects
profilassi, polmonite da Pneumocistis jiroveci, cotrimossazolo, cotrimossazolo, profilassi, polmonite da Pneumocistis jiroveci
Published
2012

30. Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer

Author

Terenziani, M., primary, Massimino, M., additional, Magazzù, D., additional, Gandola, L., additional, Capri, G., additional, Carcangiu, M.L., additional, Catania, S., additional, Di Russo, A., additional, Gennaro, M., additional, Meazza, C., additional, Podda, M., additional, Schiavello, E., additional, and Valagussa, P., additional

Published
2015
Full Text
View/download PDF

37. Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee

Author

Casanova, M, Ferrari, A, Collini, P, Bisogno, Gianni, Alaggio, Rita, Cecchetto, Giovanni, Gronchi, A, Meazza, C, Garaventa, A, Di Cataldo, A, Carli, MODESTO OTTAVIANO, and Italian Soft Tissue Sarcoma Committee

Subjects
Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Epithelioid sarcoma, Soft Tissue Neoplasms, Proximal-Type Epithelioid Sarcoma, Internal medicine, proximal-type epithelioid sarcoma, medicine, Humans, Child, Lymph node, epithelioid sarcoma, Survival analysis, nonrhabdomyosarcoma soft tissue sarcoma, Retrospective Studies, pediatric soft tissue sarcomas, lymph node metastases, business.industry, Soft tissue sarcoma, Cancer, Retrospective cohort study, Sarcoma, medicine.disease, Prognosis, Combined Modality Therapy, Survival Analysis, Surgery, Radiation therapy, medicine.anatomical_structure, Oncology, Child, Preschool, Lymphatic Metastasis, Female, Neoplasm Recurrence, Local, business
Abstract

BACKGROUND Epithelioid sarcoma (ES) is an uncommon malignant soft tissue tumor. To the authors' knowledge, little information is available to date concerning its clinical features and management in children and adolescents, particularly with regard to the recently described proximal-type variant. The current study concerns 30 patients age < 18 years who were enrolled in the Italian Soft Tissue Sarcoma Committee protocols. METHODS Histopathologic specimens, clinical data, and treatment modalities were reviewed for the current analysis. Nineteen patients had classic ES and 11 had proximal-type ES. Surgery was the mainstay of treatment; radiotherapy was given to six patients considered to be at risk of local disease recurrence due to incomplete resection, and chemotherapy was administered to eight patients. RESULTS With a median follow-up of 66 months, the 5-year event-free survival (EFS) and overall survival (OS) rates were 61.7% and 92.4%, respectively, but the OS rate dropped to 86.9% and 72.4%, respectively, at 10 years and 15 years. Local disease recurrence was the major cause of treatment failure. The most significant finding influencing both EFS and OS was tumor site, with a tumor location in the extremities predicting a favorable outcome. Initially unfavorable clinical findings and a worse outcome were associated with the proximal-type variant of ES. A response to chemotherapy was noted in three of the seven patients with measurable disease. CONCLUSIONS The current study confirms some typical features of ES (i.e., the peculiar superficial distal location [i.e., the hand, fingers], indolent growth, and a tendency to recur locally). The current study data do not clearly confirm the strong tendency for the lymph node involvement described in adult ES patients. Further studies are needed to better define the clinical behavior and biology of the proximal-type variant of ES. Cancer 2006. © 2005 American Cancer Society.

Published
2006

39. Syndrome of GH bioinactivity: myth or reality?

Author

Bozzola, M., Travaglino, P., Poddighe, D., Pagani, S., Meazza, C., Mancini, L., Iughetti, Lorenzo, De Sanctis, V., Salti, R., Neri, A. S., Salvatoni, A., Cerutti, P., and Tinelli, C.

Subjects
bioactivity, Growth hormone
Published
2005

42. QUALITY OF LIFE/AFTERCARE

Author

Strobel, K., primary, Simpson, P., additional, Donohoue, P., additional, Firat, S., additional, Jogal, S., additional, Lai, J.-S., additional, Beaumont, J., additional, Goldman, S., additional, Huang, C., additional, Barrera, M., additional, Rokeach, A., additional, Hancock, K., additional, Cataudella, D., additional, Schulte, F., additional, Chung, J., additional, Bartels, U., additional, Janzen, L., additional, Sung, L., additional, Strother, D., additional, Hukin, J., additional, Downie, A., additional, Zelcer, S., additional, Atenafu, E., additional, Schiavello, E., additional, Biassoni, V., additional, Meazza, C., additional, Podda, M., additional, Massimino, M., additional, Wells, E. M., additional, Ullrich, N. J., additional, Seidel, K., additional, Leisenring, W., additional, Sklar, C., additional, Armstrong, G. T., additional, Diller, L., additional, King, A., additional, krull, K., additional, Neglia, J. P., additional, Stovall, M., additional, Whelan, K., additional, Robison, L. L., additional, Packer, R. J., additional, Remes, T., additional, Harila-Saari, A., additional, Suo-Palosaari, M., additional, Lahteenmaki, P., additional, Arikoski, P., additional, Riikonen, P., additional, Rantala, H., additional, Ojaniemi, M., additional, Bull, K., additional, Kennedy, C., additional, Bailey, S., additional, Ellison, D., additional, Clifford, S., additional, Dembowska-Baginska, B., additional, Brozyna, A., additional, Drogosiewicz, M., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Filipek, I., additional, Tarasinska, M., additional, Korzeniewska, J., additional, Perek, D., additional, Salgado, D., additional, Nunes, S., additional, Pereira, P., additional, Vinhais, S., additional, Salih, S., additional, Elsarrag, S., additional, Prange, E., additional, Contreas, K., additional, Possin, P., additional, Frierdich, S., additional, Eickhoff, J., additional, Puccetti, D., additional, Ladas, E., additional, Buck, C., additional, Arbit, N., additional, Gudrunardottir, T., additional, Lannering, B., additional, Remke, M., additional, Taylor, M. D., additional, Keating, R. F., additional, Stapleton, S., additional, Flanary, J., additional, Hamblin, F., additional, Amankwah, E., additional, Ghazarian, S., additional, Jagt, C. T., additional, van de Wetering, M., additional, Schouten-van Meeteren, A. Y. N., additional, Nowinski, C., additional, Hartsell, W., additional, Chang, J. H.-C., additional, Cella, D., additional, Krishna, U., additional, Nagrulkar, A., additional, Takle, M., additional, Kannan, S., additional, Gupta, T., additional, Jalali, R., additional, Northman, L., additional, Morris, M., additional, Ross, S., additional, Guo, D., additional, Chordas, C., additional, Liptak, C., additional, Delaney, B., additional, Ullrich, N., additional, Manley, P., additional, Avula, S., additional, Pizer, B., additional, Ong, C. C., additional, Harave, S., additional, Mallucci, C., additional, Kumar, R., additional, Margol, A., additional, Finlay, J., additional, Dhall, G., additional, Robison, N., additional, Krieger, M., additional, Kiehna, E., additional, Coates, T., additional, Nelson, M., additional, Grimm, J., additional, Evans, A., additional, Nelson, M. B., additional, Britt, B., additional, Cooksey, R., additional, Wu, S., additional, Gode, A., additional, Klesse, L., additional, Oden, J., additional, Vega, G., additional, Gargan, L., additional, Bowers, D., additional, Madden, J. R., additional, Prince, E., additional, Zeitler, P., additional, Foreman, N. K., additional, and Liu, A. K., additional

Published
2014
Full Text
View/download PDF

44. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis

Author

De Benedetti, F., Meazza, C., Vivarelli, M., Rossi, F., Pistorio, A., Lamb, R., Lunt, M., Thomson, W., Abinun, M., Becker, M., Bell, A., Craft, A., Crawley, E., David, J., Foster, H., Gardener-Medwin, J., Griffin, J., Hall, A., Hall, M., Herrick, A., Hollingworth, P., Holt, L., Jones, S., Pountain, G., Ryder, C., Southwood, T., Stewart, I., Venning, H., Wedderburn, L., Woo, P., Wyatt, S., Ravelli, A., Donn, R., and Martini, A.

Subjects
Questionnaires, Adolescent, drug therapy/genetics/metabolism/physiopathology, Health Status, genetics/metabolism, Enzyme-Linked Immunosorbent Assay, Severity of Illness Index, Juvenile Rheumatoid, Drug Therapy, Synovial Fluid, Humans, Point Mutation, Genetic Predisposition to Disease, Polymorphism, Child, Preschool, Glucocorticoids, Macrophage Migration-Inhibitory Factors, Retrospective Studies, Adolescent, Antirheumatic Agents, therapeutic use, Arthritis, drug therapy/genetics/metabolism/physiopathology, Child, Child, Preschool, Drug Therapy, Combination, Enzyme-Linked Immunosorbent Assay, Genetic Predisposition to Disease, Glucocorticoids, therapeutic use, Health Status, Humans, Infant, Macrophage Migration-Inhibitory Factors, genetics/metabolism, Point Mutation, Polymorphism, Single Nucleotide, Prognosis, Questionnaires, Retrospective Studies, Severity of Illness Index, Synovial Fluid, metabolism, Treatment Outcome, Arthritis, Infant, Single Nucleotide, Prognosis, Treatment Outcome, Antirheumatic Agents, therapeutic use, Combination, metabolism
Published
2003

Catalog

Books, media, physical & digital resources
See catalog results